Mevalonate Kinase Deficiency

This is a rare genetic condition. It affects how your body makes cholesterol. Because of this, a substance called mevalonic acid builds up in your body. This buildup causes various symptoms, including developmental delays, eye problems like cataracts, enlarged liver and spleen, balance issues, and sometimes fevers and rashes. It's inherited from parents.

Condition

What people with Mevalonate Kinase Deficiency report

Every report comes from a Lived member, sent anonymously.

Have you tried Interleukin 1 Receptor Antagonist Protein for Mevalonate Kinase Deficiency?

NameHow it went

About Mevalonate Kinase Deficiency

What It Is

Mevalonate kinase deficiency (MKD) is a rare inherited condition that causes repeated episodes of fever and body-wide inflammation, usually starting in the first year of life. A typical episode lasts about three to six days and can bring swollen lymph nodes, abdominal pain, diarrhea, joint pain, skin rash and headache, sometimes with painful mouth sores. Episodes tend to be most frequent in childhood, as often as 25 times a year in some children, and usually become less frequent with age. MKD is an autoinflammatory disease, meaning the innate immune system, the body's first-line defense, switches on inflammation without an infection to fight. It comes in two forms on a spectrum. The milder and far more common form, long called hyper-IgD syndrome (HIDS), causes fever episodes, and people usually feel well between them. The severe form, mevalonic aciduria, causes problems all the time, not only during fevers: developmental delay, poor balance and coordination, seizures, progressive vision problems and slow growth.

Causes & Risk Factors

MKD is caused by changes (variants) in the MVK gene, which carries the instructions for an enzyme called mevalonate kinase. It is inherited in an autosomal recessive pattern: a person has MKD when both copies of the gene are affected, one from each parent. Parents who each carry one copy usually have no symptoms, and each of their children has a one-in-four chance of inheriting MKD. The condition has been found worldwide but is reported more often in people of Northern European, particularly Dutch, ancestry. How much working enzyme remains largely determines which form a person has. Some residual activity tends to produce the milder, episodic form, while almost none produces mevalonic aciduria. Even people with the same gene variants can be affected differently. Once someone has MKD, episodes can be set off by vaccinations, infections, surgery, injury or emotional or physical stress, and many come with no clear trigger. Because the enzyme works less well at higher temperatures, any illness with a fever can itself tip a person into a flare.

How It's Diagnosed

Diagnosis usually begins with a child or adult who has fevers that keep returning with a recognizable pattern, often from infancy, and no infection to explain them. Blood tests taken during an episode, such as C-reactive protein (CRP) and serum amyloid A (SAA), confirm that the body is inflamed. They do not identify MKD on their own, and they often return to normal between episodes. Genetic testing of the MVK gene is the key step and is recommended whenever MKD is suspected. Finding disease-causing variants in both copies confirms the diagnosis. Results can be hard to interpret, so they are best reviewed by a specialist in autoinflammatory diseases, and genetic counseling is offered to the family. A urine test for mevalonic acid can support the diagnosis, but in the milder form the level is usually raised only during a fever, so the sample needs to be collected during an episode. Despite the old name, blood levels of the antibody immunoglobulin D (IgD) are no longer recommended as a test: they are normal in some people with MKD and raised in other diseases. Other causes of recurrent fever, including infections and other periodic fever syndromes, are considered along the way.

Treatment Options

There is no treatment that corrects the enzyme problem itself in most people, but treatment can shorten or prevent episodes and protect long-term health. The aim is fewer and milder flares, normal inflammation blood tests between them and, in children, normal growth. Mild flares may be eased with nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, although these alone are often not enough. A short course of a corticosteroid such as prednisone, started early in an episode, can calm a flare, but steroids are not suited to long-term use because of their side effects. For people with frequent or disruptive episodes, the main treatment is a medicine that blocks interleukin-1 (IL-1), an immune signaling protein that drives the inflammation. Canakinumab (Ilaris), an injection usually given every four to eight weeks, is approved in the US for MKD in adults and children. In a placebo-controlled trial, about a third of people taking it had their flare resolve with no new flare by 16 weeks, compared with about 6 percent on placebo, and with longer treatment most had no flares at all. Some people need higher or more frequent doses. Anakinra (Kineret), a daily injection, is used off label, either continuously or at the first sign of an episode. Because these medicines dampen part of the immune system, they increase the risk of serious infections, and live vaccines should not be given at the same time as canakinumab. When IL-1 blockers do not work well enough, specialists may try other biologic medicines. Statins, the cholesterol medicines that act on the same chemical pathway, are not recommended for MKD. For the most severe cases that do not respond to other treatment, a stem cell transplant can bring lasting remission, but it carries a serious risk of life-threatening complications and is reserved for a small number of people.

What to Expect

For most people with the milder form, MKD is a long-term condition of interrupted rather than continuous illness, with a normal life expectancy. Before effective treatment, people commonly lost weeks of school or work each year to episodes. With IL-1 blocking treatment, many people have far fewer flares or none, and quality of life and children's growth often improve. Episodes usually become less frequent in adulthood, although they do not always stop. Care is usually led by a specialist team in autoinflammatory diseases, often a rheumatologist or immunologist. Follow-up typically includes inflammation blood tests at least every three months, regular urine tests to look for protein (an early sign of amyloidosis, a rare complication in which inflammation-related protein deposits damage the kidneys) and, in children, growth checks every three to six months. Keeping a diary of episodes and their triggers helps the team judge whether treatment is working. Vaccinations can bring on a flare, but routine vaccines are still recommended where possible, because the infections they prevent are more dangerous than a flare. Plan vaccines with the specialist, especially if taking a biologic medicine. Mevalonic aciduria follows a different course. Children need ongoing support for development, movement, seizures, vision and nutrition. The outlook varies widely: the most severely affected children may live only into early childhood, while more mildly affected people can live into adulthood.

When to Seek Help

Arrange an evaluation if a child or adult has fevers that keep coming back in a pattern, especially with swollen glands, abdominal pain, diarrhea or rash, and no infection is found. It is also worth asking for a review if episodes are becoming more frequent or longer, or if current treatment is not keeping them under control. Contact the care team promptly if you take canakinumab, anakinra or another biologic medicine and develop signs of a possible infection that feel different from your usual flares, such as a cough that will not go away or symptoms in one specific area, or if an episode lasts well beyond its usual length. Check with the team before any planned vaccine or surgery so flares and treatment can be managed around it.

Questions to Ask Your Doctor

  1. 1.Do my genetic results confirm MKD, and which form does this point to?
  2. 2.How often do flares need to happen before continuous treatment such as canakinumab makes sense?
  3. 3.How can I tell a flare from an infection while I am on a biologic medicine?
  4. 4.Which tests will we use to check for silent inflammation and kidney involvement, and how often?
  5. 5.What does this mean for other family members or for future children?

Last reviewed • Oct 2026

Educational content, not medical advice.